Thus, using antibodies to directly block those negative immunological regulators (checkpoints) proved to be an important strategy for cancer immunity; particularly, the PD-1/PD-L1 inhibitors have shown signs of efficacy for different cancer treatments [10]. Here, PDCD1 is linked to cancer.